Continued follow-up of the United Kingdom Collaborative HIV Cohort (UK CHIC) and the UK HIV Drug Resistance Database (UK HDRD), 2014-2019

2014-2019 年英国艾滋病毒协作队列 (UK CHIC) 和英国艾滋病毒耐药数据库 (UK HDRD) 的持续随访

• 批准号: MR/M004236/1
• 负责人: Caroline Sabin
• 金额: $ 270.8万
• 依托单位: University College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2014
• 资助国家: 英国
• 起止时间: 2014 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FM004236%2F1
• 关键词: Continued; follow; up; United; Kingdom

The number of people living with the human immunodeficiency virus (HIV) in the UK continues to increase. Current treatment for HIV is very effective and, as a result, the life expectancy of a person living with HIV has increased substantially over the past 15 years. However, HIV remains extremely costly to the National Health Service and there are still many challenges that must be faced to ensure that people with HIV continue to live full and healthy lives. In particular, some people continue to experience side effects on treatment - these may be life-threatening, may lead to a reduction in quality-of-life, and may limit the drugs that patients can receive in the future. If patients are unable to take their treatment for periods of time, then virus may grow that is resistant to some of the currently available drugs. An increasing number of HIV-positive people are living to older age, which may also lead to an increase in the side effects that are seen as well as an increase in general age-related illness. In addition, many HIV-positive children are also surviving into adulthood - as yet, we have little information on the outcomes of this group as they switch their care to adult HIV clinics. A proportion of people with HIV in the UK are also infected with hepatitis C virus (HCV) which has implications for the timing and choice of treatments that can be used. Whilst HCV has traditionally been hard to treat in those who also have HIV, some of the newly available HCV drugs offer greater promise of a cure for HCV. However, a large-scale assessment of the use of these drugs in people also infected with HIV remains to be undertaken. There are therefore many questions that must be addressed to ensure that the outcomes of those living with HIV are optimised. In particular, although it is often said that people with HIV can expect to live a 'near-normal' lifespan, whether this will ultimately be possible is far from clear. In order to plan the need for health care services and to understand the need for new drugs, it is essential that any changes in the characteristics of the UK epidemic are monitored.Since 2001, the UK Collaborative HIV Cohort (CHIC) Study has followed people with HIV in the UK, to monitor their use of treatments against HIV and their outcomes. The UK HIV Drug Resistance Database (UK HDRD) collects information on the results of any tests that are performed to determine whether the virus that infects these individuals has become resistant to any of the currently used treatments. The latest dataset includes data on >45,000 patients attending 16 clinics and is one of the largest such collaborations worldwide. This application is for continued support of the combined UK CHIC Study and UK HDRD until 2019 for the following reasons:1. To study the outcomes of people with HIV in the UK, including a description of the drugs that are used and any resistance that may develop; 2. To better understand of how HIV spreads between and within subgroups of the population; 3. To assess whether new and infrequently encountered strains of HIV are likely to respond less well to treatment; 4. To describe the use of new treatments for HCV in study participants, and to describe the success of these treatments, particularly in people who may get re-infected with HCV on multiple occasions;5. To describe the outcomes of HIV-positive adolescents who switch their HIV care from paediatric to adult services and to model the likely problems that might result as the HIV population ages;6. To explore the extent to which genetic factors might contribute to the outcomes of HIV and its treatment;7. To investigate the potential effects of treatment, side effects and resistance on life expectancy in HIV-positive people.A secondary aim is to continue to ensure that the UK plays a leading role in international HIV cohort research through the provision of high quality data to international studies.

英国感染人类免疫缺陷病毒（HIV）的人数继续增加。目前的艾滋病毒治疗非常有效，因此，艾滋病毒感染者的预期寿命在过去15年中大幅增加。然而，艾滋病毒对国家卫生服务来说仍然是极其昂贵的，仍然必须面对许多挑战，以确保艾滋病毒感染者继续过上充实和健康的生活。特别是，有些人继续经历治疗的副作用-这些副作用可能危及生命，可能导致生活质量下降，并可能限制患者将来可以接受的药物。如果患者在一段时间内无法接受治疗，那么病毒可能会对目前可用的一些药物产生耐药性。越来越多的艾滋病毒阳性者活到老年，这也可能导致副作用的增加以及与年龄有关的一般疾病的增加。此外，许多艾滋病毒抗体阳性儿童也能活到成年----迄今为止，我们对这一群体在转向成人艾滋病毒诊所治疗后的结果知之甚少。在英国，一部分艾滋病毒感染者也感染了丙型肝炎病毒（HCV），这对可以使用的治疗的时机和选择有影响。虽然HCV在传统上很难治疗那些也有HIV的人，但一些新的HCV药物提供了治愈HCV的更大希望。然而，对这些药物在也感染艾滋病毒的人中的使用情况仍有待进行大规模评估。因此，必须解决许多问题，以确保艾滋病毒感染者的成果得到优化。特别是，尽管人们经常说艾滋病毒感染者可以预期过上“接近正常”的寿命，但这最终是否可能还远不清楚。为了规划对医疗保健服务的需求和了解对新药的需求，监测英国流行病特征的任何变化至关重要。自2001年以来，英国艾滋病毒合作队列研究（CHIC）一直在跟踪英国艾滋病毒感染者，以监测他们使用艾滋病毒治疗及其结果。英国艾滋病毒耐药性数据库（英国HDRD）收集有关任何测试结果的信息，以确定感染这些人的病毒是否对目前使用的任何治疗产生耐药性。最新的数据集包括超过45，000名参加16家诊所的患者的数据，是全球最大的此类合作之一。此申请是为了继续支持英国CHIC研究和英国HDRD，直到2019年，原因如下：1。研究英国艾滋病毒感染者的结果，包括对所用药物的描述和可能产生的任何耐药性; 2.更好地了解艾滋病毒如何在人口亚群之间和内部传播; 3.评估新的和不常见的艾滋病毒毒株是否可能对治疗反应不佳; 4.描述研究参与者使用新的HCV治疗方法，并描述这些治疗方法的成功，特别是在可能多次再次感染HCV的人群中;5.描述艾滋病毒阳性青少年将艾滋病毒护理从儿科服务转向成人服务的结果，并模拟随着艾滋病毒感染者年龄的增长可能导致的问题;探讨遗传因素在多大程度上可能对艾滋病及其治疗的结果产生影响;7.调查治疗的潜在影响，副作用和耐药性对HIV阳性人群的预期寿命的影响。次要目的是通过向国际研究提供高质量的数据，继续确保英国在国际HIV队列研究中发挥主导作用。

项目成果

Non-Hodgkin lymphoma risk in adults living with HIV across five continents.

• DOI: 10.1097/qad.0000000000002003
• 发表时间: 2018-11-28
• 期刊: AIDS (London, England)
• 作者: AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord

Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals.

• DOI: 10.1097/md.0000000000005133
• 发表时间: 2016-10
• 期刊: Medicine
• 影响因子: 1.6
• 作者: Cain LE;Caniglia EC;Phillips A;Olson A;Muga R;Pérez-Hoyos S;Abgrall S;Costagliola D;Rubio R;Jarrín I;Bucher H;Fehr J;van Sighem A;Reiss P;Dabis F;Vandenhende MA;Logan R;Robins J;Sterne JAC;Justice A;Tate J;Touloumi G;Paparizos V;Esteve A;Casabona J;Seng R;Meyer L;Jose S;Sabin C;Hernán MA;HIV-CAUSAL Collaboration
• 通讯作者: HIV-CAUSAL Collaboration

Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK.

• DOI: 10.1111/hiv.13096
• 发表时间: 2021-09
• 期刊: HIV medicine
• 影响因子: 3
• 作者: Asad H;Collins IJ;Goodall RL;Crichton S;Hill T;Doerholt K;Foster C;Lyall H;Post FA;Welch S;Winston A;Sabin CA;Judd A;Collaborative HIV Paediatric Study (CHIPS) Steering Committee, the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committee
• 通讯作者: Collaborative HIV Paediatric Study (CHIPS) Steering Committee, the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committee

Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: collaborative cohort analysis.

• DOI: 10.1097/qad.0000000000000941
• 发表时间: 2016-01-28
• 期刊: AIDS (London, England)
• 作者: Antiretroviral Therapy Cohort Collaboration (ART-CC);Canadian Observational Cohort Collaboration (CANOC);UK Collaborative HIV Cohort Study (UK CHIC);Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)
• 通讯作者: Collaboration of Observational HIV Epidemiological Research in Europe (COHERE)

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

• DOI: 10.1093/cid/ciw562
• 发表时间: 2016-11
• 期刊: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
• 作者: N. Wyss;M. Zwahlen;G. Clifford;M. Campbell;R. Chakraborty;F. Bonnet;G. Chêne;F. Bani-Sadr;A. Verbon;R. Zangerle;V. Paparizos;M. Prins;F. Dronda;V. Moing;A. Antinori;E. Quiros-Roldan;C. Mussini;J. Miró;L. Meyer;J. Vehreschild;N. Obel;A. Mocroft;N. Brockmeyer;F. Boué;C. Sabin;V. Spagnuolo;B. Hasse;S. Wit;B. Roca;M. Egger;J. Bohlius